Winthrop-University Hospital Cardiac Team One of First on L.I. to Use Drug-Coated Stent During Surgery

Vol. 13, No. 2
July, 2003

  • The Winthrop Legacy: People That Made a Difference in Our Community

  • Winthrop-University Hospital Cardiac Team One of First on L.I. to Use Drug-Coated Stent During Surgery

  • Winthrop-University Hospital Announces Anti-Slime Compound Could Be Used on Space Station

  • Winthrop-University Hospital Physicians Perform Groundbreaking New Procedure to Decrease Recurrance of Coronary Artery Blockages

  • Winthrop Puts Golfers in The Swing of Things

  • Garden City High School Seniors 'Pay it Forward' for Patients at Winthrop-University Hospital

  • Winthrop's Pediatric Task Force Leads Fundraising Initiative for New Pediatric Inpatient Center

  • Winthrop-University Hospital Helps Seniors Sort Out Mysteries of Medication

  • Winthrop-University Hospital Orthopaedic Surgeon Performs New, Small Incision Minimally Invasive Hip Replacement Procedure

  • Winthrop-University Hospital's 2nd Hispanic Health Fair Successfully Reaches Out to Hundreds in Community

  • Winthrop-South Nassau University Health System Joins New York's Largest Healthcare System

  • Golden Goose Gala Visits The Roaring 20s - Save the Date - November 15, 2003!

    Back to Publications

  • Kevin Marzo, MD (center) inserts the new drug eluting stent into a patient. Looking on are Jennifer Quackenbush, CVT and S. Medha, MD.
    Patients suffering from coronary artery disease now have access to a new generation of technology that promises to reduce trips to the hospital for repeat procedures. A team of interventional cardiologists at Winthrop-University Hospital has become one of the first on Long Island to utilize the new FDA approved drug-releasing stent to keep heart arteries open following angioplasty procedures.

    Kevin Marzo, MD, Chief of Winthrop's Department of Cardiology, was one of the first Long Island physicians to insert one of the newly approved drug-coated stents into a patient. In less than 24 hours, Winthrop's team of interventional cardiologists had deployed 15 of these much-anticipated stents into their patients. "This breakthrough technology promises to dramatically improve outcomes for many thousands of heart patients undergoing angioplasty and stent placement as a treatment for their coronary artery disease," said Dr. Marzo.

    Ralph and Maryann Napolitano, (left) Jay's World Childhood Cancer Foundation Founders present a $50,000 check to John P. Broder, Vice President, External Affairs & Development at Winthrop, fulfilling their first $100,000 pledge to help build a patient oncology room in Winthrop's Pediatric Inpatient Center which is currently under construction. After reviewing renderings and plans of the new Center, they enthusiastically made a second $100,000 commitment to further underwrite the cost of building inpatient rooms in the new center for children with cancer.
    Heart disease is due to narrowing of the coronary arteries, reducing the amount of blood that reaches the heart muscles, often leading to symptoms of angina. If the artery becomes completely blocked, a heart attack will result. One way to treat a narrowed artery is to reopen it using a tiny balloon-a surgical technique called angioplasty-and then hold it open with a tiny wire mesh tube called a stent.

    However, there has been a concern that the opened artery will gradually narrow again over time. To overcome this problem, a new drug-coated stent can now be inserted into an artery-slowly releasing the drug sirolimus, a compound traditionally used to prevent organ transplant rejection. It is the first such stent approved in the United States.

    By coating the stent in a drug that will prevent the overgrowth of cells lining blood vessels and discourage the formation of scar tissue near the stent, this device is expected to revolutionize the treatment of coronary artery disease and significantly cut the rate of artery re-narrowing, or restenosis, following angioplasty procedures. Restenosis occurs in about a third of the stenting procedures performed in the United States each year.

    "Patients who receive this new stent will need fewer repeat surgeries," continued Dr. Marzo. "And, the reduced risk of recurrence will allow cardiologists to treat many blockages that are currently not easily treated."

    For further information, contact Winthrop-University Hospital's Department of Cardiology in the Institute for Heart Care at (516) 663-2396.

    [ Home | Search | Contact | Directions | Privacy Notice ]

    Winthrop-University Hospital | 259 First Street | Mineola NY 11501 | 516-663-0333

    This site provides information as a resource. It is not a substitute for professional medical advice.
    Always consult a physician or healthcare provider for treatment and guidance toward good health.
    Copyright © 2008 Winthrop-University Hospital. All rights reserved. Long Island Web Design